Allogene Therapeutics, Inc.
NASDAQ:ALLO
2.13 (USD) • At close December 31, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0.095 | 0.243 | 38.489 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 242.914 | 16.728 | 13.065 | 11.541 | 5.027 | 1.5 | 0 |
| Gross Profit
| -242.819 | -16.485 | 25.424 | -11.541 | -5.027 | -1.5 | 0 |
| Gross Profit Ratio
| -2,555.989 | -67.84 | 0.661 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 242.914 | 256.387 | 220.176 | 192.987 | 144.535 | 151.86 | 0 |
| General & Administrative Expenses
| 71.673 | 79.305 | 74.105 | 65.256 | 57.473 | 40.982 | 0.024 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -0.022 |
| SG&A
| 71.673 | 79.305 | 74.105 | 65.256 | 57.473 | 40.982 | 0.002 |
| Other Expenses
| 13.245 | -1.749 | -2.927 | -1.142 | -0.268 | -21.211 | 0 |
| Operating Expenses
| 327.832 | 335.692 | 294.281 | 258.243 | 202.008 | 192.842 | 0.002 |
| Operating Income
| -327.737 | -335.449 | -255.792 | -258.243 | -202.008 | -192.842 | -0.002 |
| Operating Income Ratio
| -3,449.863 | -1,380.449 | -6.646 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.472 | -4.878 | -1.859 | 8.022 | 17.083 | -18.78 | -0.022 |
| Income Before Tax
| -327.265 | -332.632 | -257.005 | -250.221 | -184.925 | -211.622 | -0.002 |
| Income Before Tax Ratio
| -3,444.895 | -1,368.856 | -6.677 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -2.817 | -12.168 | -16.75 | -0.331 | -0.117 | -0.024 |
| Net Income
| -327.265 | -329.815 | -244.837 | -233.471 | -184.594 | -211.505 | -0.002 |
| Net Income Ratio
| -3,444.895 | -1,357.263 | -6.361 | 0 | 0 | 0 | 0 |
| EPS
| -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | 0 |
| EPS Diluted
| -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | 0 |
| EBITDA
| -300.293 | -321.241 | -169.738 | -250.808 | -179.898 | -206.764 | 0.022 |
| EBITDA Ratio
| -3,160.979 | -1,380.449 | -6.646 | 0 | 0 | 0 | 0 |